ArticleHuman genomics2026
Genetic findings in ten Ecuadorian patients with suspected Wilson's disease.
Article in Human genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWilson disease is a rare autosomal recessive disorder caused by variations in ATP7B, leading to copper accumulation and multisystemic damage. Diagnosis is often delayed due to its heterogeneous clinical presentation and limited genetic data in underrepresented populations.
methodsWe characterized ten Ecuadorian patients with clinical suspicion of Wilson disease using whole-exome sequencing (WES), selected to enable simultaneous assessment of ATP7B and other metabolic genes relevant to Wilson-like phenotypes. Variants were interpreted following HGNC and ACMG/AMP guidelines. Ancestry was examined in nine patients using ADMIXTURE and PCA with a reference panel of 968 individuals from African, European, and Indigenous American populations. ATP7B expression was quantified by RT-qPCR in the one patient lacking identifiable coding-region variants.
resultsSix patients were homozygous and two were compound heterozygous for pathogenic or likely pathogenic ATP7B variants. The recurrent alleles c.2052dupC p.(Met685*) (Guayaquil) and c.2012_2013insAT p.(Met671Ilefs*) (Cañar/Cuenca) showed geographic and ancestry patterns consistent with known demographic structure in Ecuador, though not sufficient to infer founder effects. Additional variants included c.3188 C > T p.(Ala1603Val), c.3727 C > G p.(Leu1243Val), c.2318G > A p.(Cys773Tyr), and c.2080 C > T p.(Arg694Trp). One patient with no detectable ATP7B coding-region variation demonstrated ~ 9.8-fold reduced ATP7B expression, supporting the clinical diagnosis.
conclusionsThis study provides an integrated clinical, molecular, and ancestry framework for characterizing Wilson disease in an underrepresented population. The identification of regionally recurrent ATP7B variants, together with the diversity of clinical presentations, highlights the need for comprehensive diagnostic approaches in admixed populations. Larger studies incorporating segregation and functional assays will be essential to refine variant interpretation and improve access to molecular diagnosis in Latin America.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.